Skip to main content

Advertisement

Log in

Patient and Physician Satisfaction with Proton Pump Inhibitors (PPIs): Are There Opportunities for Improvement?

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background

Few studies have explored the satisfaction with proton pump inhibitors (PPIs) for gastroesophageal reflux disease (GERD).

Aim

The aim of this study was to assess patient and physician satisfaction with currently prescribed PPIs for patients with GERD.

Methods

Separate online surveys were completed by 1,002 physicians and 1,013 GERD patients. Physician surveys examined satisfaction, symptom relief, long-term therapy, side-effects, breakthrough symptoms, and use of supplemental medications with PPIs. Patient surveys evaluated PPI regimen, length of therapy, satisfaction with PPI, symptom relief, use of supplemental medications, and perceptions about long-term use and side-effects.

Results

Most respondents were satisfied with PPI therapy, but 35.4% of GERD patients and 34.8% of physicians perceived patients as “somewhat satisfied” to “completely dissatisfied” with PPI therapy. Patients who were highly satisfied were more likely to indicate complete symptom relief (P < 0.001) relative to patients who were less satisfied. However, over 35% of patients on once-daily and 54% on twice-daily PPI indicated that therapy failed to completely relieve symptoms. Patients who were highly satisfied were more likely to recommend medication to patients with the same symptoms (P < 0.001) and less likely to report that the medication is too expensive (P < 0.001), worry about long-term use (P < 0.001), or add OTC medications for supplemental control (P < 0.004).

Conclusions

Approximately one-third of GERD patients reported persistent symptoms and were dissatisfied with PPI therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Notes

  1. PCP categorization included general practitioners, family practitioners, internal medicine practitioners, and osteopathic practitioners.

References

  1. Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology. 2002;122:1500–1511.

    Article  PubMed  Google Scholar 

  2. Armstrong D. Systematic review: persistence and severity in gastroesophageal reflux disease. Aliment Pharmacol Ther. 2008;28:841–853.

    CAS  PubMed  Google Scholar 

  3. Vakil N. Review article: New pharmacological agents for the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2004;19:1041–1049.

    Article  CAS  PubMed  Google Scholar 

  4. Calabrese C, Fabbri A, Di Febo G. Long-term management of GERD in the elderly with pantoprazole. Clin Intery Aging. 2007;2:85–92.

    Article  CAS  Google Scholar 

  5. Pettit M. Treatment of gastroesophageal reflux disease. Pharm World Sci. 2005;27:432–435.

    Article  PubMed  Google Scholar 

  6. Becker V, Bajbouj M, Waller K, Schmid RM, Meining A. Clinical trial: persistent gastro-oesophageal reflux symptoms despite standard therapy with proton pump inhibitors—a follow-up study of intraluminal-impedance guided therapy. Aliment Pharmacol Ther. 2007;26:1355–1360.

    Article  CAS  PubMed  Google Scholar 

  7. National Digestive Diseases Information Clearinghouse (NDDIC): Heartburn, gastroesophageal reflux (GER), and gastroesophageal reflux disease (GERD). Available at: http://digestive.niddk.nih.gov/ddiseases/pubs/gerd/. Accessed Aug 28, 2008.

  8. Liker H, Hungin P, Wiklund I. Managing gastroesophageal reflux disease in primary care: the patient perspective. J Am Board Fam Pract. 2005;18:393–400.

    Article  PubMed  Google Scholar 

  9. Bretagne JF, Honnohat C, Richard-Mollard B, Caekkaerts A, Barthelemys P. Comparative study of characteristics and disease management between subjects with frequent and occasional gastro-oesophageal reflux symptoms. Aliment Pharmacol Ther. 2006;23:607–616.

    Article  CAS  PubMed  Google Scholar 

  10. Kulig M, Leodolter A, Vieth M, et al. Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease—an analysis based on the ProGERD initiative. Aliment Pharmacol Ther. 2003;18:767–776.

    Article  CAS  PubMed  Google Scholar 

  11. Wahlqvist P, Karlsson M, Johnson D, Carlsson J, Bolge SC, Wallander MA. Relationship between symptom load of gastro-esophageal reflux disease and health-related quality of life, work productivity, resource utilization and concomitant diseases: survey of a US cohort. Aliment Pharmacol Ther. 2008;27:960–970.

    Article  CAS  PubMed  Google Scholar 

  12. Crawley JA, Schmitt CM. How satisfied are chronic heartburn sufferers with their prescription medications? Results of the patient unmet needs survey. J Clin Outcomes Manag. 2000;7:29–34.

    Google Scholar 

  13. Donnellan C, Sharma N, Preston C, Moayyedi P. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev. 2004;2:CD003245.

    Google Scholar 

  14. Robinson M, Shaw K. Proton pump inhibitor attitudes and usage: a patient survey. Pharm Ther. 2002;27:202–206.

    Google Scholar 

  15. Hatlebakk JG, Katz PO, Camacho-Lobato L, Castell DO. Proton pump inhibitors: better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther. 2000;14:1267–1272.

    Article  CAS  PubMed  Google Scholar 

  16. Hunt R, Yuan Y, Yaghoobi M. GERD: new strategies and new failures. J Clin Gastroenterol. 2007;41(Supp 2):S72–S80.

    Article  Google Scholar 

  17. Mainie I, Tutuian R, Shay S, et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut. 2006;55:1398–1402.

    Article  CAS  PubMed  Google Scholar 

  18. Rubenstein JH, Nojkov B, Korsnes S, et al. Esophageal hypersensitivity is associated with features of psychiatric disorders and the irritable bowel syndrome. Aliment Pharmacol Ther. 2007;26:443–452.

    Article  CAS  PubMed  Google Scholar 

  19. Nojkov B, Saad R, Adlis S, Shaw M, Chey WD. Predictors of response to PPI therapy in patients with GERD: the influence of co-morbid IBS and psychological disease. Aliment Pharmacol Ther. 2008;27:473–482.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors wish to recognize the writing assistance provided by Meg Franklin, PharmD, PhD, an associate with Xcenda, L.L.C.

Disclosures

Financial Support: The study was funded by Takeda Pharmaceuticals North America, Inc.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to William D. Chey.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chey, W.D., Mody, R.R. & Izat, E. Patient and Physician Satisfaction with Proton Pump Inhibitors (PPIs): Are There Opportunities for Improvement?. Dig Dis Sci 55, 3415–3422 (2010). https://doi.org/10.1007/s10620-010-1209-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-010-1209-2

Keywords

Navigation